Good practice statement on the use of variant-containing COVID-19 vaccines

This Good Practice Statement on the use of variant-containing COVID-19 vaccines was updated on the basis of advice by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 28 September 2023.

The updated recommendations made by TAG-CO-VAC and this Good Practice Statement synthesize current evidence on variant-containing COVID-19 vaccines, notably those containing XBB. This document contains some off-label recommendations . In this document, the terms “primary series” and “initial doses” are used interchangeably, and so are the terms “additional doses “ and “booster doses”.